This trial is testing whether the immunotherapy drug pembrolizumab is better than the standard chemotherapy treatment for women with endometrial cancer that is resistant to other treatments.
2 Primary · 11 Secondary · Reporting Duration: Up to approximately 49 months
Active Control
Experimental Treatment
350 Total Participants · 2 Treatment Groups
Primary Treatment: pembrolizumab · No Placebo Group · Phase 3
Age 18+ · Female Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: